Armata Pharmaceuticals, Inc. announced a delay in its fourth quarter and full-year 2025 financial results announcement, anticipating filing its Form 10-K on or before March 31, 2026, and provided a corporate update including FDA QIDP designation for AP-SA02, Phase 3 trial plans, cGMP facility commissioning, and positive Phase 2a study results.
Key takeaways
Delayed Q4 and FY 2025 financial results announcement; 10-K filing by 2026-03-31.
FDA granted QIDP designation to AP-SA02 for adjunct treatment of complicated S. aureus bacteremia caused by MSSA or MRSA.
End-of-Phase 2 FDA response confirms advancement of AP-SA02 to Phase 3 study in complicated SAB, initiation anticipated in H2 2026.
cGMP manufacturing facility in Los Angeles, California (56,000 sq ft) formally commissioned with full production runs completed.
Phase 2a diSArm study of AP-SA02 showed higher cure rate at day 12, 100% response without relapse, and trends toward rapid normalization of mortality predictors.
Submitted FDA request for Fast Track Designation for AP-SA02.